4D Molecular Therapeutics Inc.

17/07/2024 | Press release | Distributed by Public on 18/07/2024 02:23

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.